Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Pre-Close Trading Update

19 May 2020 07:00

RNS Number : 2669N
Ideagen PLC
19 May 2020
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

19 May 2020

 

Ideagen PLC

("Ideagen," "the Company" or the "Group'')

 

Pre-Close Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, is pleased to provide an update on trading for the year ended 30 April 2020 and the outlook entering the new financial year.

 

The publication of the Company's full year results for the period to 30 April 2020 will be slightly later than normal this year and are expected to be published on or around the 22nd September 2020. This follows discussions with the Company's advisers and auditors and is due to the prevailing circumstances surrounding the COVID-19 pandemic and the practical difficulties that it will impose upon the audit process.

 

 

Trading Statement

 

The Board is pleased to report that trading for the year to 30 April 2020 was strong and results are expected to be in line with market expectations. This represents the Group's eleventh consecutive year of revenue and adjusted EBITDA* growth.

 

The Group expects to report revenue up 21% at approximately ÂŁ56.6million as compared to ÂŁ46.7million in the previous financial year. Adjusted EBITDA* is expected to be up 29% to approximately ÂŁ18.5m on an IFRS16 basis and, on a like-for-like IAS17 basis, up 22% to approximately ÂŁ17.5m.

 

The Board considers Annual Recurring Revenue (ARR) as its primary growth metric and the driver for long term value. ARR recognised during the year is expected to be ÂŁ43.1m, representing an increase to 76% of total revenues from 67% the previous year. The ARR book as at 30 April 2020 was up 34% to approximately ÂŁ48.7 million from ÂŁ36.4 million, arising from both strong organic growth of approximately 19% on the previous year and acquired ARR from three acquisitions made within the year.

 

It is particularly pleasing to note that the organic growth was driven by 458 new customer logo wins across verticals such as Healthcare, Life Sciences, Financial Services and US Government, with new customers including the US Federal Reserve, SSE, Emirates and Corbus Pharmaceuticals. Investment appetite from new customers in sectors that have been more intensely impacted by the pandemic, including the Aviation and Manufacturing sectors, has as expected been slower. Reflecting the importance of the Group's software to our customers, there has been no material impact on the Group's existing customer relationships or the ARR book as a result of COVID-19.

 

Cash generated by operations was ahead of expectations at over 95% of adjusted EBITDA*, resulting in a gross cash balance of ÂŁ8.2m and gross bank borrowings of ÂŁ25.0m at the period end. Net bank debt at the year end of ÂŁ16.8m was lower than anticipated and comfortably within banking covenants. As a result, the Group remains in a robust financial position.

 

Outlook

 

 

The Board reiterates the guidance it provided on 7 April 2020. Ideagen's software is considered business critical by our customers and this, together with a strong ARR book, gives the Board confidence that the ÂŁ15m run rate revenue from the final quarter of previous financial year will continue as expected. The Group has also implemented a prudent cost reduction programme that has generated approximately ÂŁ4m in annual savings.

 

In light of this, the Group believes it has the right financial model to meet market expectations for the current year and continues to intend to pay a dividend in respect of the financial year in line with its progressive dividend policy. The Group expects to declare this dividend at its full year results in line with its normal practice.

 

 

 

 

Ben Dorks, Chief Executive commented:

 

"We are pleased to report that despite the impact of COVID-19, the Group has continued to perform well in delivering yet another year of quality earnings growth underpinned by strong cash generation. The Group has now successfully transitioned to primarily a recurring revenue model and has quickly responded to the new and challenging business backdrop we all face. I would like to thank all our employees who have displayed great resilience and fortitude during these difficult times".

 

 

*Earnings before interest, tax, depreciation, amortisation, share based payments, acquisition costs and other exceptional items.

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

 

Ben Dorks, Chief Executive

 

Graeme Spenceley, Finance Director

 

 

 

 

 

 

finnCap Limited

 

020 7220 0500

Henrik Persson, James Thompson (NOMAD)

 

Alice Lane (ECM)

 

 

 

 

Canaccord Genuity Limited

 

020 7523 8000

Simon Bridges, Richard Andrews

 

 

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 6,000 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTVVLFFBELLBBZ
Date   Source Headline
25th Jun 20147:00 amRNSAcquisition of EIBS Ltd
5th Jun 20142:06 pmRNSHolding(s) in Company
3rd Jun 20147:00 amRNSIssue of ordinary shares
16th May 20147:00 amRNSIssue of ordinary shares
7th May 20147:00 amRNSTrading Update and Further NHS Contract Wins
17th Mar 20147:00 amRNSNHS Contract Wins
4th Mar 20147:00 amRNSContract Wins and Trading Update
20th Jan 201411:54 amRNSHolding(s) in Company
14th Jan 20147:00 amRNSHalf Yearly Report
3rd Jan 20144:41 pmRNSSecond Price Monitoring Extn
3rd Jan 20144:35 pmRNSPrice Monitoring Extension
17th Dec 20137:00 amRNSNotice of Results
20th Nov 20137:00 amRNSAcquisition of Pentana Ltd
6th Nov 20137:00 amRNSTrading update
30th Oct 201312:22 pmRNSAnnual Report & Accounts
29th Oct 20132:38 pmRNSResult of AGM
16th Oct 201312:02 pmRNSHolding(s) in Company
8th Oct 20137:00 amRNSIssue of ordinary shares
7th Oct 20137:00 amRNSNotice of AGM
9th Sep 20137:00 amRNSFurther Healthcare Contract Wins
16th Jul 20137:01 amRNSFinal Results
16th Jul 20137:00 amRNSNew Contract Win worth £300k
9th Jul 20137:00 amRNSNotice of Results
3rd Jul 20137:00 amRNSAcquisition of MSS Management Systems Services Ltd
10th Jun 20137:00 amRNSStrategic Partnership
10th May 20131:15 pmRNSDirector/PDMR Shareholding
10th May 20137:00 amRNSVA Contract Update
7th May 20137:00 amRNSTrading Update
22nd Apr 20137:00 amRNSContract Wins and Trading Update
19th Mar 20132:39 pmRNSHolding(s) in Company
12th Mar 20137:00 amRNSContract Wins and Board Change
31st Jan 20137:00 amRNSIssue of Equity and Award of Options
22nd Jan 20137:00 amRNSHalf Yearly Report
16th Jan 20137:00 amRNSHealthcare Contract Wins and New Appointments
16th Jan 20137:00 amRNSHolding(s) in Company
10th Jan 20137:00 amRNSNotice of Results
7th Jan 201312:55 pmRNSResult of General Meeting and Issue of Equity
24th Dec 20121:07 pmRNSHolding(s) in Company
24th Dec 201212:21 pmRNSHolding(s) in Company
19th Dec 20123:00 pmRNSPosting of Circular and Notice of General Meeting
17th Dec 20127:00 amRNSPlacing and acquisition
29th Nov 20127:00 amRNSTrading Update
9th Nov 20124:16 pmRNSHolding(s) in Company
31st Oct 20121:40 pmRNSResult of AGM
10th Oct 20125:57 pmRNSHolding(s) in Company
8th Oct 201211:42 amRNSNotice of AGM and Change of Address
3rd Sep 20128:25 amRNSHolding(s) in Company
29th Aug 20127:00 amRNSHolding(s) in Company
29th Aug 20127:00 amRNSContract Win
24th Jul 20127:00 amRNSPreliminary Results 30 April 2012

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.